O.101 A novel primboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: A phase IIa clinical trial
Titel:
O.101 A novel primboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: A phase IIa clinical trial
Auteur:
Schneider, J. Halota, W. Delic, D. Nesic, Z. Prokopowicz, D. Flisiak, R. Kuydowicz, J. Jablkowski, M. Cianciara, J. Mach, T. Modrzewska, R. Fabri, M. Tomic, D. Horban, A. Krycka, W. Cripps, M.